AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28199070 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 302
Study 28199070 — intervention group
Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 302
Study 25881268 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs and eye masks combined with 30-minute relaxing music
Number of subjects: 50
Study 25881268 — intervention group
Group type: COMPARATOR
Intervention: Control group (no earplugs, eye masks, or music)
Number of subjects: 50
Study 23890600 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital polysomnography (PSG)
Number of subjects: 160
Study 23890600 — intervention group
Group type: COMPARATOR
Intervention: Postdischarge polysomnography (PSG)
Number of subjects: 160
Study 21383291 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day oral aprepitant regimen (125 mg on day 1, 80 mg on day 2, 80 mg on day 3)
Number of subjects: 2247
Study 21383291 — intervention group
Group type: COMPARATOR
Intervention: Single-dose intravenous fosaprepitant (150 mg on day 1)
Number of subjects: 2247
Study 18504592 — intervention group
Group type: EXPERIMENTAL
Intervention: MR enteroclysis
Number of subjects: 30
Study 18504592 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy (Rutgeerts score)
Number of subjects: 30
Study 16052688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with esophageal varices (EVB +)
Number of subjects: 120
Study 16052688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients without esophageal variceal bleeding (EVB -)
Number of subjects: 120
Study 16052688 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120
Study 16052688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with F1 varices
Number of subjects: 120
Study 16052688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with F2 and F3 varices
Number of subjects: 120
Study 16052688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with hepatofugal flow velocity >15 cm/s
Number of subjects: 120
Study 16052688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients after glucose ingestion
Number of subjects: 120
Study 16052688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with hepatofugal blood flow in the LGV
Number of subjects: 120
Study 10583029 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (0.44 mg day-1, 0.88 mg day-1, 1.76 mg day-1)
Number of subjects: 12
Study 10583029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (5 mg day-1, 10 mg day-1, 20 mg day-1)
Number of subjects: 12
Study 10583029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9060066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum KLD (10^10) b.i.d. for 4 weeks
Number of subjects: 17
Study 9060066 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 17
Study 1652264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg pipecuronium
Number of subjects: 41
Study 1652264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg pipecuronium
Number of subjects: 41
Study 1652264 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 41
Study 1652264 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 41
Study 1652264 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study 6848299 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 6
Study 6848299 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 6
Study 6848299 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg
Number of subjects: 6
Study 6848299 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 400 mg
Number of subjects: 6
Study 6848299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31998163 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 0
Study 31998163 — intervention group
Group type: COMPARATOR
Intervention: Recreational Therapy (RT)
Number of subjects: 0
Study 29278709 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring (mean of 16.3 scans/day)
Number of subjects: 50831
Study 27649854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 25274860 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxus stents
Number of subjects: 242
Study 25274860 — intervention group
Group type: COMPARATOR
Intervention: BMS
Number of subjects: 242
Study 25274860 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxus and BMS combined
Number of subjects: 242
Study 23161305 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography
Number of subjects: 95
Study 23161305 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance cholangiopancreatography
Number of subjects: 95
Study 18704471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (60 mg BD)
Number of subjects: 105
Study 18704471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine and nasal corticosteroids
Number of subjects: 105
Study 18704471 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne pollen exposure for 4 days prior to the study
Number of subjects: 105
Study 18704471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative amount of airborne pollen during the treatment period
Number of subjects: 105
Study 18704471 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic history
Number of subjects: 105
Study 18780501 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Number of subjects: 60
Study 18780501 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator appliance
Number of subjects: 60
Study 18780501 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbst appliance
Number of subjects: 60
Study 16045138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron prophylaxis
Number of subjects: 34
Study 16045138 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 34
Study 11982836 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone premedication with halothane
Number of subjects: 130
Study 11982836 — intervention group
Group type: COMPARATOR
Intervention: Halothane without oxycodone
Number of subjects: 130
Study 11982836 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane without oxycodone
Number of subjects: 130
Study 11982836 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone premedication with sevoflurane
Number of subjects: 130
Study 10593449 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 12.5 mg/day for the first week, then 25 mg/day for the remaining weeks (8 weeks total)
Number of subjects: 27
Study 8618109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 10 mg/kg bid for 5 days
Number of subjects: 120
Study 8618109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 10 mg/kg bid for 10 days
Number of subjects: 120
Study 8618109 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin 25,000 U/kg tid for 10 days
Number of subjects: 120
Study 2169839 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (15 ml bd)
Number of subjects: 43
Study 2169839 — intervention group
Group type: COMPARATOR
Intervention: High-fibre diet (30-40 g daily)
Number of subjects: 43
Study 7398187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 5
Study 7398187 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 2 gm in water
Number of subjects: 5
Study 7398187 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-aluminum hydroxide gel 30 ml
Number of subjects: 5
Study 7398187 — intervention group
Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 5
Study 31672946 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Health Promotion Program (CHPP) for 10 weeks, weekly sessions, including coping strategies, lifestyle modification, emotional support, and exercise three times a week at home
Number of subjects: 62
Study 31672946 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study 29712566 — intervention group
Group type: EXPERIMENTAL
Intervention: VRP (2.0) distal radius plate (Austofix)
Number of subjects: 200
Study 29712566 — intervention group
Group type: COMPARATOR
Intervention: VA-LCP (Variable angle-locking plate) (Depuy-Synthes)
Number of subjects: 200
Study 29712566 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200
Study 26096162 — intervention group
Group type: EXPERIMENTAL
Intervention: Conical interface (CI)
Number of subjects: 141
Study 26096162 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat-to-flat interface (FI)
Number of subjects: 141
Study 26096162 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform switch interface (PS)
Number of subjects: 141
Study 26096162 — intervention group
Group type: COMPARATOR
Intervention: All groups (CI, FI, PS)
Number of subjects: 141
Study 24055737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 69
Study 24055737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 22467891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine block
Number of subjects: 12
Study 22467891 — intervention group
Group type: COMPARATOR
Intervention: Placebo block
Number of subjects: 12
Study 19859781 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (S)
Number of subjects: 21
Study 19859781 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 21
Study 19859781 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 17852171 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (n = 177)
Number of subjects: 239
Study 17852171 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (n = 62)
Number of subjects: 239
Study 15745977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase (250,000 IU twice daily for three days)
Number of subjects: 454
Study 15745977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study 15745977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase
Number of subjects: 454
Study 12414852 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T(4))
Number of subjects: 123
Study 12414852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 10492650 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 15
Study 10492650 — intervention group
Group type: EXPERIMENTAL
Intervention: CO
Number of subjects: 15
Study 8961992 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch-gelatin group
Number of subjects: 69
Study 8961992 — intervention group
Group type: COMPARATOR
Intervention: Gelatin-only group
Number of subjects: 69
Study 1742507 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bismuth therapy
Number of subjects: 44
Study 1742507 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine therapy
Number of subjects: 44
Study 6125728 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg acyclovir by mouth five times a day for 5 days
Number of subjects: 116
Study 6125728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 31931762 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralised NCD care delivered by nurse practitioners in community clinics
Number of subjects: 1125
Study 29659406 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical BTX‐A liposomal cream
Number of subjects: 20
Study 29659406 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 20
Study 26704774 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg) plus lidocaine (1.5 mg/kg)
Number of subjects: 110
Study 26704774 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg) plus normal saline 0.9% (placebo)
Number of subjects: 110
Study 25338456 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrations of nitric oxide
Number of subjects: 0
Study 25338456 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity of oxistat
Number of subjects: 0
Study 23724549 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step adhesives (XE)
Number of subjects: 8
Study 23724549 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step adhesives (GB)
Number of subjects: 8
Study 23724549 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step adhesives (CS3)
Number of subjects: 8
Study 23724549 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step adhesives (AD)
Number of subjects: 8
Study 23724549 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step adhesives (GO)
Number of subjects: 8
Study 23724549 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step adhesives (1-step ABSE)
Number of subjects: 8
Study 23724549 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step adhesives (2-step ABSE)
Number of subjects: 8
Study 23724549 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step adhesives (CSE)
Number of subjects: 8
Study 23724549 — intervention group
Group type: COMPARATOR
Intervention: Control (CSE)
Number of subjects: 8
Study 23724549 — intervention group
Group type: COMPARATOR
Intervention: Control (2-step ABSE)
Number of subjects: 8
Study 23724549 — intervention group
Group type: COMPARATOR
Intervention: Control (1-step ABSE)
Number of subjects: 8
Study 23724549 — intervention group
Group type: COMPARATOR
Intervention: Control (AD)
Number of subjects: 8
Study 23724549 — intervention group
Group type: COMPARATOR
Intervention: Control (CS3)
Number of subjects: 8
Study 23724549 — intervention group
Group type: COMPARATOR
Intervention: Control (GB)
Number of subjects: 8
Study 23724549 — intervention group
Group type: COMPARATOR
Intervention: Control (GO)
Number of subjects: 8
Study 23724549 — intervention group
Group type: COMPARATOR
Intervention: Control (XE)
Number of subjects: 8
Study 19757215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib in patients with prior cytokine therapy
Number of subjects: 903
Study 19757215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib in cytokine-naïve patients
Number of subjects: 903
Study 19757215 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with prior cytokine therapy
Number of subjects: 903
Study 19757215 — intervention group
Group type: COMPARATOR
Intervention: Placebo in cytokine-naïve patients
Number of subjects: 903
Study 18755514 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-60 mg daily, flexible-dose)
Number of subjects: 518
Study 18755514 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 518
Study 16780494 — intervention group
Group type: EXPERIMENTAL
Intervention: 1072-nm light treatment
Number of subjects: 0
Study 16780494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14645972 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial biopsy during bronchoscopy
Number of subjects: 33
Study 14645972 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopy without endobronchial biopsy (Control)
Number of subjects: 33
Study 14645972 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial biopsy
Number of subjects: 33
Study 10808173 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen nasal challenges
Number of subjects: 20
Study 10808173 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal challenges
Number of subjects: 20
Study 10808173 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Allergen and Placebo)
Number of subjects: 20
Study 10808173 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen group
Number of subjects: 20
Study 8822535 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 45
Study 8822535 — intervention group
Group type: EXPERIMENTAL
Intervention: dextroamphetamine
Number of subjects: 45
Study 8822535 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study 8822535 — intervention group
Group type: EXPERIMENTAL
Intervention: pemoline
Number of subjects: 45
Study 1532613 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 16
Study 1532613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 4067130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ppm of sulfur dioxide (SO2) via oral inhalation
Number of subjects: 10
Study 4067130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ppm of sulfur dioxide (SO2) via oronasal inhalation (face mask)
Number of subjects: 10
Study 4067130 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/m3 of sulfuric acid (H2SO4)
Number of subjects: 10
Study 4067130 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (sham exposure)
Number of subjects: 10
Study 4067130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ppm of sulfur dioxide (SO2)
Number of subjects: 10
Study 30240978 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive-behavioral therapy (CBT4CBT) plus treatment as usual (TAU)
Number of subjects: 19
Study 30240978 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment as usual (TAU)
Number of subjects: 19
Study 29271269 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious trauma-writing condition
Number of subjects: 105
Study 29271269 — intervention group
Group type: COMPARATOR
Intervention: Conventional trauma-writing condition
Number of subjects: 105
Study 26320407 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum SMS reminders
Number of subjects: 276
Study 26320407 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to postpartum OGTT completion
Number of subjects: 276
Study 26320407 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators for postpartum OGTT completion
Number of subjects: 276
Study 24439741 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted subcuticular suture
Number of subjects: 293
Study 24439741 — intervention group
Group type: COMPARATOR
Intervention: Interrupted transdermal suture
Number of subjects: 293
Study 22960288 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg, single subcutaneous injection)
Number of subjects: 0
Study 22960288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20456282 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip contraction at 40% of maximal voluntary contraction force
Number of subjects: 0
Study 20456282 — intervention group
Group type: COMPARATOR
Intervention: Additional pressure changes induced by inflating bilateral thigh cuffs
Number of subjects: 0
Study 18799552 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 340
Study 18799552 — intervention group
Group type: COMPARATOR
Intervention: Control group (23-valent pneumococcal polysaccharide vaccine)
Number of subjects: 340
Study 15707442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive coping intervention administered over three consecutive days in 20-30 minute sessions.
Number of subjects: 0
Study 15707442 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 12125806 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) and hormone replacement therapy (HRT)
Number of subjects: 0
Study 10091752 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (transthoracic esophagectomy with limited lymphadenectomy)
Number of subjects: 99
Study 10091752 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (50 gray in 28 fractions followed by a 15-gray boost to the primary tumor)
Number of subjects: 99
Study 10091752 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 99
Study 10091752 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 99
Study 8585885 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant implants
Number of subjects: 16282
Study 2140370 — intervention group
Group type: EXPERIMENTAL
Intervention: TCMP‐80 (0.01 mg/kg to 10 mg/kg)
Number of subjects: 4
Study 2140370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 2140370 — intervention group
Group type: EXPERIMENTAL
Intervention: TCMP‐80
Number of subjects: 4
Study 375686 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg mianserin
Number of subjects: 54
Study 375686 — intervention group
Group type: COMPARATOR
Intervention: 150 mg imipramine
Number of subjects: 54
Study 30945492 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (puncturing specific acupoints below the spinous processes from T3 to T12, once every other day for 8 weeks)
Number of subjects: 60
Study 30945492 — intervention group
Group type: COMPARATOR
Intervention: Medication group (omeprazole capsules 20 mg, twice a day for 8 weeks)
Number of subjects: 60
Study 28796688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy first (group A)
Number of subjects: 68
Study 28796688 — intervention group
Group type: COMPARATOR
Intervention: Biopsy first (group B)
Number of subjects: 68
Study 26028518 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT; goserelin 10·8 mg every 3 months for 3 years) plus four cycles of docetaxel (70 mg/m² on day 2) and estramustine (10 mg/kg per day on days 1-5, every 3 weeks)
Number of subjects: 413
Study 26028518 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) only
Number of subjects: 413
Study 26028518 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (data available for patients treated with radiotherapy)
Number of subjects: 413
Study 26028518 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related deaths
Number of subjects: 413
Study 26028518 — intervention group
Group type: EXPERIMENTAL
Intervention: Second cancers
Number of subjects: 413
Study 23645180 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-bed DALK
Number of subjects: 64
Study 23645180 — intervention group
Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 64
Study 17265078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (15 mg/day)
Number of subjects: 20